An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Stoke Therapeutics, Inc. (NASDAQ: STOK), a biotechnology firm focused on RNA-based therapies, has announced participation in two investor conferences this November. The Credit Suisse 30th Annual Healthcare Conference will take place on November 10, 2021, at 10:30 a.m. ET, followed by the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 3:20 p.m. ET. Live webcasts of the presentations will be available on Stoke's website, with replays accessible for 30 days afterwards. Stoke is advancing therapies for severe diseases via its proprietary TANGO approach.
Positive
None.
Negative
None.
BEDFORD, Mass.--(BUSINESS WIRE)--
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at two upcoming investor conferences in November.
Credit Suisse 30th Annual Healthcare Conference
Date: Wednesday, November 10, 2021 Time: 10:30 a.m. ET
Stifel 2021 Virtual Healthcare Conference Date: Monday, November 15, 2021 Time: 3:20 p.m. ET
A live audio webcast of each presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the presentations.
About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The Company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the Company’s belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts, with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the Company on Twitter at @StokeTx.
